What is Elephas?
Elephas operates at the intersection of biotechnology and diagnostic innovation, developing a tumor-agnostic platform that predicts patient response to immunotherapy treatments. The company's core technology utilizes live tissue from biopsies to measure therapeutic efficacy within a 72-hour window. By preserving the native tumor microenvironment—including the intricate interplay of genes, proteins, and immune cells—Elephas provides oncologists and pharmaceutical developers with a high-fidelity model for evaluating treatment efficacy. This capability is critical for accelerating drug development pipelines and ensuring that patients receive the most effective therapies based on their unique biological profiles, thereby reducing the trial-and-error approach currently prevalent in cancer care.
How much funding has Elephas raised?
Elephas has raised a total of $136.5M across 3 funding rounds:
Series B
$41.5M
Series C
$55M
Other Financing Round
$40M
Series B (2022): $41.5M, investors not publicly disclosed
Series C (2024): $55M led by State of Wisconsin - Investment Board, Northpond Ventures, Arch Ventures, and Sands Capital
Other Financing Round (2025): $40M supported by Northpond Ventures, ARCH VENTURE PARTNERS, Tao Capital Management, and Sands Capital
Key Investors in Elephas
Northpond Ventures
Northpond Ventures is dedicated to advancing science and technology to create significant impacts on humanity, focusing on identifying and supporting breakthrough innovations.
ARCH VENTURE PARTNERS
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies.
Sands Capital
Sands Capital Management is an established investment firm that manages equity mutual funds and invests in public equity markets.
What's next for Elephas?
With this latest strategic financing, Elephas is well-positioned to scale its operations and expand the clinical utility of its platform across multiple cancer indications. The company is expected to focus on deepening its partnerships with pharmaceutical entities to streamline drug development cycles and enhance the predictive accuracy of its diagnostic tools. As the firm transitions into a more mature phase of its lifecycle, the focus will likely shift toward broader commercial adoption and the integration of its technology into standard clinical workflows, ultimately aiming to establish a new benchmark for personalized immunotherapy management.
See full Elephas company page
